Biotech Values

[DewDiligence]

ENTA hires RSV researcher/clinician as VP, Translation Virology:

https://www.enanta.com/investors/news-releases/press-release/2021/Enanta-Pharmaceuticals-Announces-the-Appointment-of-John-P.-DeVincenzo-M.D.-as-Vice-President-of-Translational-Virology/default.aspx

Enanta Pharmaceuticals…today announced the appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology.

In this role, Dr. DeVincenzo will provide leadership and direction for Enanta’s pipeline of respiratory antiviral clinical development programs and be responsible for the strategic development and tactical implementation of the clinical studies for these programs.

Dr. DeVincenzo brings more than 30 years of clinical research and academic experience to Enanta, predominantly focused on the pathogenesis of respiratory syncytial virus (RSV) in children and the development of therapeutic and prevention strategies for RSV and other respiratory viral diseases. …Dr. DeVincenzo has a B.S. in Biology from Stanford University and received his M.D. from Vanderbilt University School of Medicine. He completed his residency in Pediatrics at University of California, Los Angeles and a fellowship in Pediatric Infectious Disease at Boston Children’s Hospital. Dr. DeVincenzo is the author of over 250 original published abstracts and papers on the pathogenesis of RSV in children.